Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HDL Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Mendelian Reverse Cholesterol Transport Study

NCT01782027
View directory record Official record
Conditions
Cholesterol, HDL, Lipid Metabolism, Inborn Errors, Tangier Disease, LCAT Deficiency, Cholesteryl Ester Transfer Protein (CETP) Deficiency
Interventions
3H-cholesterol bound to albumin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Phase 3 Interventional

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

NCT05079919
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Not applicable Interventional

Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism

NCT01803594
View directory record Official record
Conditions
Dyslipidemia
Interventions
Krill Oil, Lutein, Nicotinic acid, Dairy phospholipids, Control
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

NCT00568594
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
APL180, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment

NCT00819403
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
simvastatin, ezetimibe/simvastatin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Phase 4 Interventional Results available

Niacin and Endothelial Function in Early CKD

NCT00852969
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Niacin, Active Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Sep 4, 2026, 9:39 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux

NCT04061018
View directory record Official record
Conditions
Lipid Metabolism Disorders
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 4, 2026, 9:39 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Goji Berry and Vasomotor Symptoms Pilot Study

NCT07660315
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Goji Berry Juice Powder, Goji Berry Powder
Other
Lead sponsor
University of California, Davis
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 4, 2026, 9:39 PM EDT
Not listed Not applicable Interventional

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

NCT03135184
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia, HoFH
Interventions
HDL Therapeutics PDS-2 System
Device
Lead sponsor
HDL Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Not applicable Interventional

From Research to Practice - Lipid Management for Low HDL-Cholesterol

NCT00057044
View directory record Official record
Conditions
Physicians' Practice Patterns, Coronary Heart Disease
Interventions
education and reminder
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
11,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 4, 2026, 9:39 PM EDT
Recruiting Not applicable Interventional

Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food

NCT06988462
View directory record Official record
Conditions
Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight, Triglycerides, HDL Cholesterol
Interventions
Bottarga, Comparator
Other
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sommerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 4, 2026, 9:39 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism

NCT01199211
View directory record Official record
Conditions
Left Ventricular Hypertrophy
Interventions
Exercise training, women, marathon
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 4, 2026, 9:39 PM EDT
Recruiting Phase 2 Interventional

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

NCT04941599
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
2-Hydroxybenzylamine, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Phase 2 Interventional

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

NCT01201837
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Placebo, CER-001
Drug
Lead sponsor
Cerenis Therapeutics, SA
Industry
Eligibility
Up to 75 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2014 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 4, 2026, 9:39 PM EDT
Completed No phase listed Observational

Evaluation of Lipoproteins

NCT00001168
View directory record Official record
Conditions
Evaluation of Plasma Lipoproteins
Interventions
Balanced diet
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
1,017 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1979
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flavonoid Effect on Activation and Stimulation of Thrombocytes, hsCRP and Lipid Profile

NCT00559663
View directory record Official record
Conditions
Healthy
Interventions
Green tea, 70% dark chocolate
Dietary Supplement
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

NCT00459745
View directory record Official record
Conditions
Combined Hyperlipidemia
Interventions
Pravafen, Pravastatin, Fenofibrate
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 75 Years
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
57
States / cities
Phoenix, Arizona • Sierra Vista, Arizona • Long Beach, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Sep 4, 2026, 9:39 PM EDT
Completed No phase listed Observational

Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins

NCT00001154
View directory record Official record
Conditions
Hypolipoproteinemia, Hypercholesterolemia, Dyslipidemia, Hyperlipidemia
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1976
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Tricor, Avandia, or Weight Loss to Lower Cardiovascular Risk Factors in People With High Triglycerides.

NCT00186537
View directory record Official record
Conditions
Insulin Resistance, Hypertriglyceridemia
Interventions
Rosiglitazone, Fenofibrate, Weight Loss
Drug · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multicenter Pilot Study to Evaluate the Effect of EVOO on Lipid Parameters

NCT04760093
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Low polyphenol concentration extra virgin olive oil (EVOO), High polyphenol concentration extra virgin olive oil (EVOO)
Dietary Supplement
Lead sponsor
Ralph Hamill
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Brunswick, Maine • Rockport, Maine • Scarborough, Maine
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Sep 4, 2026, 9:39 PM EDT
Terminated Phase 3 Interventional Results available

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases

NCT02697136
View directory record Official record
Conditions
Familial Hypoalphalipoproteinemia
Interventions
CER-001, Placebo
Drug
Lead sponsor
Cerenis Therapeutics, SA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 4, 2026, 9:39 PM EDT
Completed Not applicable Interventional

Effect of a Grape Seed Extract (GSE) on Insulin Resistance

NCT01889368
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Grape Seed Extract, Placebo
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 4, 2026, 9:39 PM EDT